Sutro Biopharma, Inc. ( Sutro Biopharma)

Primary tabs

Sutro Biopharma's picture

Management

Contact Address

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc., located in South San Francisco, develops best-in-class antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy, including Immuno-Oncology therapies. Sutro’s discovery and development efforts are driven by our proprietary Xpress CF™ and Xpress CF+™ platforms, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships, as well as rapid and predictable scalability for manufacturing in Sutro’s cGMP facility.

Sutro Biopharma press release, blog etc

Thu, 12/18/2025 - 02:28 Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Wed, 12/03/2025 - 12:39 Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
Thu, 11/06/2025 - 03:05 Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Mon, 11/03/2025 - 14:21 Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
Tue, 07/22/2025 - 08:21 Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
Mon, 06/02/2025 - 13:25 Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
Tue, 04/29/2025 - 01:55 Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
Sun, 03/16/2025 - 07:15 Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Tue, 03/04/2025 - 03:10 Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Wed, 12/11/2024 - 23:15 Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRME-O1 Trial in Platinum Resistant Ovarian Cancer
Thu, 08/22/2024 - 08:51 Sutro Biopharma Announces Initiation of REFRME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Wed, 07/10/2024 - 13:12 Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
Wed, 05/01/2024 - 17:59 Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRME-O1 Trial
Sun, 06/26/2022 - 20:40 Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
Wed, 01/05/2022 - 19:44 Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Mon, 12/27/2021 - 07:33 Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer
Mon, 12/27/2021 - 00:06 Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
Mon, 12/13/2021 - 12:28 Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021